These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24258145)

  • 61. Russia through the prism of the world biopharmaceutical market.
    Bairamashvili DI; Rabinovich ML
    Biotechnol J; 2007 Jul; 2(7):801-17. PubMed ID: 17615600
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
    [No Abstract]   [Full Text] [Related]  

  • 63. Research and development costs for drugs.
    Riggs TL
    Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
    [No Abstract]   [Full Text] [Related]  

  • 64. 2013 Statistics for global prescription medications: CNS therapeutics maintain a leading position among small molecule therapeutics.
    Lindsley CW
    ACS Chem Neurosci; 2014 Apr; 5(4):250-1. PubMed ID: 24735159
    [No Abstract]   [Full Text] [Related]  

  • 65. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regulation of clinical research sponsored by pharmaceutical companies: a proposal.
    Sotelo J
    PLoS Med; 2006 Jul; 3(7):e306. PubMed ID: 16805651
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Merck moves into biotech.
    Kling J
    Nat Biotechnol; 2006 Jul; 24(7):730. PubMed ID: 16841041
    [No Abstract]   [Full Text] [Related]  

  • 68. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmaceutical marketing in a new age. Effective campaigns still need to focus on what customers want.
    Rao SK
    Mark Health Serv; 2002; 22(1):6-12. PubMed ID: 11881547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Blockbusters for cheap? The difficulties surrounding generic biologics.
    Josephson SA; Johnston SC; Hauser SL
    Ann Neurol; 2013 Sep; 74(3):A7-8. PubMed ID: 24115256
    [No Abstract]   [Full Text] [Related]  

  • 71. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 72. Biosimilars battle rages on, Amgen fights both sides.
    Senior M
    Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
    [No Abstract]   [Full Text] [Related]  

  • 73. First Chinese-made biologics slated for human trials in the West.
    Deng B
    Nat Med; 2014 Jun; 20(6):562. PubMed ID: 24901550
    [No Abstract]   [Full Text] [Related]  

  • 74. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms.
    Vertès AA
    Regen Med; 2014; 9(4):479-95. PubMed ID: 25159065
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The year's new drugs & biologics 2016: Part I.
    Graul AI; Pina P; Cruces E; Stringer M
    Drugs Today (Barc); 2017 Jan; 53(1):27-74. PubMed ID: 28387385
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Product quality considerations for mammalian cell culture process development and manufacturing.
    Gramer MJ
    Adv Biochem Eng Biotechnol; 2014; 139():123-66. PubMed ID: 23748351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.